Position in ARVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$5,875,984
-$19,431,102 QoQ
Shares Held
707,098
-70.4% QoQ
Ownership
1.08%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
#17
of 198 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TCG Crossover Management, LLC holds $3,891,479,135 across 48 Biotechnology names. ARVN ranks #44 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
6,007,834 | $800,603,958 | |
| 2 | TNGX |
Tango Therapeutics, Inc.
|
9,081,201 | $283,878,343 | |
| 3 | CGON |
CG Oncology, Inc.
|
3,670,206 | $260,768,136 | |
| 4 | COGT |
Cogent Biosciences, Inc.
|
4,854,436 | $187,866,673 | |
| 5 | IMVT |
Immunovant, Inc.
|
4,457,988 | $171,766,277 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
1,900,582 | $168,733,669 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,676,624 | $163,437,307 | |
| 8 | MIRM |
Mirum Pharmaceuticals, Inc.
|
1,062,049 | $124,334,076 |
All Filings in ARVN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,875,984 | 707,098 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $25,307,086 | 2,387,461 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $31,621,321 | 2,666,216 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $13,779,949 | 1,617,365 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||